What happened with BMEA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Biomea Fusion, Inc. is a clinical-stage drug developer focused on two investigational oral medicines: icovamenib for type 1 and type 2 diabetes and obesity, and BMF-650 for obesity. Neither is approved, and the company has not generated revenue. Its business depends substantially on advancing these two programs through development and into commercial use.
Biomea Fusion retains worldwide development and commercialization rights to its candidates. It plans to sell approved medicines itself or with partners, but cannot commercialize them without regulatory approval. Future sales also depend on physicians prescribing the medicines and government and private payors providing adequate coverage and reimbursement.
The company relies on outside manufacturers for trial supplies and expects to use them for commercial production as well; some inputs come from single-source suppliers. It has funded operations primarily through equity financing and needs additional capital to sustain operations and development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Biomea's value hinges on diabetes and obesity trial results, but watch Eli Lilly—named in BioAge's disclosures—as an important oral GLP-1 competitor absent from this list.
Kura Oncology, Inc. directly overlaps with Biomea's lead icovamenib program by developing drugs that block menin for diabetes and cardiometabolic disorders. Its diabetes-program progress is the relevant competitive signal for Biomea, rather than its U.S. sales of the leukemia medicine KOMZIFTI.
SAB Biotherapeutics, Inc. is developing SAB-142 for autoimmune type 1 diabetes, competing for the same disease Biomea targets with icovamenib. Watch its Phase 2b SAFEGUARD study, which dosed its first patient in December 2025, for progress in this competing treatment.
Sana Biotechnology, Inc. offers a competing route to improving insulin production in type 1 diabetes: engineered pancreatic islet cell therapies rather than Biomea's small-molecule medicines.
Century Therapeutics, Inc. targets the same type 1 diabetes patients as Biomea's icovamenib, but with its CNTY-813 beta-islet cell therapy rather than an oral drug. Watch whether CNTY-813 advances toward human trials: at year-end 2025 it was in studies supporting a trial application, which Century expected to submit as early as 2026.
iBio, Inc.'s obesity antibodies could compete with Biomea's oral obesity medicines for patients and treatment budgets. Its IBIO-600 is in clinical development while its other candidates remain preclinical, making that program's progress worth watching.
BioAge Labs, Inc. is developing oral and under-the-skin obesity treatments that activate the APJ receptor, overlapping with Biomea's obesity programs. Watch those programs rather than product sales: BioAge has no approved products and receives collaboration revenue under its Novartis agreement.
Biodexa Pharmaceuticals plc competes with Biomea's icovamenib through tolimidone for type 1 diabetes, despite focusing mainly on gastrointestinal cancers. Tolimidone's development—not its cancer programs—is the news relevant to Biomea's diabetes ambitions.
Biomea Fusion, Inc. earningsThis company
Biomea Fusion has no approved products and relies on financing to fund development, so this report will show whether its cash use is matched by progress in its trials.
Read operating cash use alongside trial progress. Slower cash use with icovamenib and BMF-650 advancing would mean existing funds are supporting more development; faster cash use without matching progress would increase financing pressure and could force Biomea to cut trials or give up program rights.
Kura Oncology, Inc. earningsKURA
Kura Oncology's report will show how its diabetes menin-inhibitor program is progressing, giving Biomea Fusion's icovamenib its closest competitive comparison.
Look at the clinical stage and trial progress of Kura's diabetes program, not sales of its leukemia drug KOMZIFTI. Smooth progress would show a similar menin inhibitor advancing and put icovamenib under more direct competitive pressure; delays or setbacks could ease that near-term pressure, but would not prove icovamenib works.
